Search results
MacroGenics to Participate in Upcoming Investor Conferences
Morningstar· 4 days agoROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal ...
Uniquity Bio launches to focus on immunology and inflammation
Pharmaceutical Technology via Yahoo Finance· 14 hours agoA monoclonal antibody, solrikitug targets thymic stromal lymphopoietin. It will treat critical...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 4 days agoAlso, Lyvgen’s monoclonal antibody (mAb) dalnicastobart has seen its transition prospects increase...
Nipocalimab's Unique Mechanism Gets Second Chance in RA
Medscape· 4 days agoThe IRIS-RA study of the investigational monoclonal antibody drug nipocalimab in patients with...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 3 days agoSanofi plans to invest €1bn in Vitry-sur-Seine to construct a new unit in a bid to double the ...
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 6 days agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Sanofi to Spend $1.08 Billion to Boost Drug Production in France
Morningstar· 4 days agoSanofi will spend more than 1 billion euros ($1.08 billion) on ramping up production capability in France. The French pharmaceutical company said Monday that the bulk of the investment will ...
Fosun International Earns a Spot on "2024 Fortune China ESG Impact List"
Fort Wayne Journal Gazette· 21 hours agoOn 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun...
Intel upgraded, Texas Instruments initiated: Wall Street's top analyst calls
The Fly via Yahoo Finance· 10 hours agoH.C. Wainwright initiated coverage of Dianthus Therapeutics (DNTH) with a Buy rating and $40 price...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 2 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...